Article
NAD(P)H:Quinone oxidoreductase-1 C609T polymorphism analysis in human superficial bladder cancers: relationship of genotype status to NQO1 phenotype and clinical response to Mitomycin C.
International journal of oncology - 1 Oct 2004
Basu Saurajyoti, Brown John E, Flannigan G Michael, Gill Jason H, Loadman Paul M, Martin Sandie W, Naylor Brian, Puri Rajiv, Scally Andrew J, Seargent Jill M, Shah Tariq, Phillips Roger M
Abstract excerpt
NAD(P)H:Quinone oxidoreductase-1 (NQO1) has been implicated in the bioreductive activation of the clinically active anticancer drug Mitomycin C (MMC) and a polymorphic variant of NQO1 which lacks functional enzyme activity (NQO1*2) has been linked with poor survival in patients treated with MMC....
Topics
- Carcinoma, Transitional Cell
- Genotype
- Humans
- Mitomycin
- NAD(P)H Dehydrogenase (Quinone)
- Neoplasm Staging
- Phenotype
- Polymorphism, Genetic
- Retrospective Studies
- Urinary Bladder Neoplasms